Cytotoxicity of apigenin on leukemia cell lines: implications for prevention and therapy

Author(s)

Ruela-de-Sousa, R. R. ^{[1, 2]} ; Fuhler, G. M. ^[2] ; Blom, N. ^[2] ; Ferreira, C. V. ^[1] ; Aoyama, H. ^[1] ; Peppelenbosch, M. P. ^[2]

Affiliation

^[1] Univ Estadual Campinas, Inst Biol, Dept Biochem, Sao Paulo - Brazil

^[2] Univ Groningen, Dept Cell Biol, Univ Med Ctr Groningen, NL-9713 AV Groningen - Netherlands

• Document type: Journal article
• Source: CELL DEATH & DISEASE; v. 1, JAN 2010.
• Web of Science Citations: 81

Abstract

Natural-food-based compounds show substantial promise for prevention and biotherapy of cancers including leukemia. In general, their mechanism of action remains unclear, hampering rational use of these compounds. Herein we show that the common dietary flavonoid apigenin has anticancer activity, but also may decrease chemotherapy sensitivity, depending on the cell type. We analyzed the molecular consequences of apigenin treatment in two types of leukemia, the myeloid and erythroid subtypes. Apigenin blocked proliferation in both lineages through cell-cycle arrest in G(2)/M phase for myeloid HL60 and G(0)/G(1) phase for erythroid TF1 cells. In both cell lines the JAK/STAT pathway was one of major targets of apigenin. Apigenin inhibited PI3K/PKB pathway in HL60 and induced caspase-dependent apoptosis. In contrast, no apoptosis was detected in TF1 cells, but initiation of autophagy was observed. The block in cell cycle and induction of autophagy observed in this erythroleukemia cell line resulted in a reduced susceptibility toward the commonly used therapeutic agent vincristine. Thus, this study shows that although apigenin is a potential chemopreventive agent due to the induction of leukemia cell-cycle arrest, caution in dietary intake of apigenin should be taken during disease as it potentially interferes with cancer treatment. Cell Death and Disease (2010) 1, e19; doi:10.1038/cddis.2009.18; published online 28 January 2010 (AU)